gdc
ImmunotherapyLung Cancer

Immune Checkpoint Inhibitors Offer New Hope for Patients with Lung Cancer

Several immune checkpoint inhibitors are now approved for patients with non–small-cell lung cancer, giving hope to patients living with this disease.
November 2018 Volume 4 – Lung Cancer
Jane Morgan

Lung cancer remains the leading cause of cancer-related deaths in men and women, accounting for 1 in every 4 deaths caused by cancer in the United States. However, recent advances in immunotherapy, especially those called “immune checkpoint inhibitors,” bring new hope for patients with lung cancer.

Recommended For You
ImmunotherapyMultiple Myeloma
How CAR T-Cell Therapy Gave Cherie Rineker Her Life Back
By Kelsey Moroz
Chemotherapy for multiple myeloma had kept Cherie Rineker alive for 5 years, but then she realized she was slowly dying. So she embarked on a search for a clinical trial and by luck was able to join one. To her amazement, “What 2 stem-cell transplants and 13 other treatments had not been able to do in more than 65 months, CAR T-cell therapy did in less than 1 month,” she said.
Breast CancerFDA Approvals, News & UpdatesImmunotherapy
First Immunotherapy Approved for Patients with Advanced or Metastatic Triple-Negative Breast Cancer Expressing PD-L1
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer.
Last modified: January 4, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country